tbuckley/cabot-search huggingface dataset:
Abstract 2488: Analysis of the salivary proteome of the prolactin-inducible-protein knockout mouse
Authors: Anne Blanchard, Peyman Ezzati, Xiuli Ma, John Wilkins, Yvonne Myal
Journal: Cancer Research (2014)

Abstract The human Prolactin-Inducible-Protein (PIP)/Gross Cystic Disease Fluid Protein 15 (GCDFP-15) gene is abnormally expressed in human invasive breast cancer and gross cystic disease of the breast. In healthy individuals PIP is highly expressed in salivary, sweat and lacrimal glands, and the secreted protein abundantly found in saliva as well as other bodily fluids which bathe various ports of entry. PIP has been shown to bind numerous bacterial strains as well as a number of immunoregulatory molecules including the CD4-T cell receptor and IgG and is therefore implicated to play an immune role in host defense. In the present study we interrogated the salivary proteome of the PIP knockout (Pip KO) mouse by mass spectrometry to determine protein changes that occur in saliva in the absence of PIP. Proteomic analysis identified 165 proteins in the mouse saliva which had a minimum of 2 unique peptides at the 99% confidence level. Nineteen proteins, including 2 proposed markers of disease, S100A9 and adenosine deaminase, were significantly differentially expressed in the saliva of the Pip KO mouse, compared to the saliva of the wild type counterparts. Functional and biological determinations revealed that the differentially expressed proteins were associated with processes that include inflammatory responses, immunity and cell death. This study provides evidence that a number of proteins associated with host defense are affected by the loss of PIP, and lends support for an immunomodulatory role for PIP. Citation Format: Anne Blanchard, Peyman Ezzati, Xiuli Ma, John Wilkins, Yvonne Myal. Analysis of the salivary proteome of the prolactin-inducible-protein knockout mouse. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2488. doi:10.1158/1538-7445.AM2014-2488
Plaque Assay for the Mason-Pfizer Monkey Virus2
Authors: Kenneth H. Rand, Cedric W. Long, Tena Tang Wei, Raymond V. Gilden
Journal: JNCI Journal of the National Cancer Institute (1974)

Journal Article Plaque Assay for the Mason-Pfizer Monkey Virus Get access Kenneth H. Rand, Kenneth H. Rand Search for other works by this author on: Oxford Academic PubMed Google Scholar Cedric W. Long, Cedric W. Long Search for other works by this author on: Oxford Academic PubMed Google Scholar Tena Tang Wei, Tena Tang Wei Search for other works by this author on: Oxford Academic PubMed Google Scholar Raymond V. Gilden Raymond V. Gilden 6 6Address reprint requests to: Dr. Raymond V. Gilden, Flow Laboratories, Inc., 1710 Chapman Ave., Rockville, Md. 20852. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 53, Issue 2, August 1974, Pages 449–452, https://doi.org/10.1093/jnci/53.2.449 Published: 01 August 1974 Article history Received: 11 December 1973 Accepted: 25 April 1974 Published: 01 August 1974
Remembering Dr Walter Burgdorf
Authors: Leonard J. Hoenig
Journal: JAMA Dermatology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Recent Trends in the Identification of Incidental Pulmonary Nodules
Authors: Michael K. Gould, Tania Tang, In-Lu Amy Liu, Janet Lee, Chengyi Zheng, Kim N. Danforth, Anne E. Kosco, Jamie L. Di Fiore, David E. Suh
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

Pulmonary nodules are common incidental findings, but information about their incidence in the era of computed tomography (CT) is lacking.To examine recent trends in pulmonary nodule identification.We used electronic health records and natural language processing to identify members of an integrated health system who had nodules measuring 4 to 30 mm. We calculated rates of chest CT imaging, nodule identification, and receipt of a new lung cancer diagnosis within 2 years of nodule identification, and standardized rates by age and sex to estimate the frequency of nodule identification in the U.S. population in 2010.Between 2006 and 2012, more than 200,000 adult members underwent 415,581 chest CT examinations. The annual frequency of chest CT imaging increased from 1.3 to 1.9% for all adult members, whereas the frequency of nodule identification increased from 24 to 31% for all scans performed. The annual rate of chest CT increased from 15.4 to 20.7 per 1,000 person-years, and the rate of nodule identification increased from 3.9 to 6.6 per 1,000 person-years, whereas the rate of a new lung cancer diagnosis remained stable. By extrapolation, more than 4.8 million Americans underwent at least one chest CT scan and 1.57 million had a nodule identified, including 63,000 who received a new lung cancer diagnosis within 2 years.Incidental pulmonary nodules are an increasingly common consequence of routine medical care, with an incidence that is much greater than recognized previously. More frequent nodule identification has not been accompanied by increases in the diagnosis of cancerous nodules.
Neuropsychological functioning after CPAP treatment in obstructive sleep apnea: A meta-analysis
Authors: Justine Aaronson, Wytske Kylstra, Winni Hofman, Ben Schmand
Journal: European Respiratory Journal (2012)

Introduction:  the generally held clinical view is that treatment with continuous positive airway pressure (CPAP) substantially improves cognition in patients with obstructive sleep apnea (OSA). The cognitive domains in which recovery is found as well as the extent of recovery differs widely between studies, however.  Objective:  a meta-analysis was conducted to quantify the magnitude of the overall effect of CPAP treatment in OSA on neuropsychological functioning  Methods : a comprehensive literature search of clinical trials published from January 1990 to June 2011 was performed. The inclusion criteria were: randomized controlled trial, diagnosis OSA by polysomnography, apnea-hypopnea index, duration and compliance of CPAP treatment, one or more standardized neuropsychological tests. Mean-weighted effect sizes of CPAP treatment for 7 cognitive domains were calculated.  Results:  12 studies encompassing 516 OSA patients were included. A small significant effect on attention was observed in favour of CPAP treatment (d=.20). For the other cognitive domains the effect sizes did not reach significance. Improvement on measures of sleepiness was modest (d=.30-.40) and comparable to a prior meta-analysis.  Conclusion:  this meta-analysis shows that effect of CPAP treatment on cognition is small and limited to the attention domain. These findings indicate that, contrary to the general assumption, only slight improvement of cognitive functioning after CPAP treatment can be expected.
Association of granulocytosis with poor prognosis in patients with acute myelogenous leukemia and translocation of chromosomes 8 and 21.
Authors: S O'Brien, H M Kantarjian, M Keating, G Gagnon, A Cork, J Trujillo, K B McCredie
Journal: Journal of Clinical Oncology (1989)

Forty-three patients with acute myelogenous leukemia (AML) and a translocation 8;21 were reviewed. The patients' median age was 30 years, and 62% were men. Twenty-three patients (53%) had loss of a sex chromosome and ten (23%) had other chromosomal abnormalities in addition to the 8;21 translocation. Complete remission (CR) with induction chemotherapy was achieved in 40 patients (93%). The median CR duration was 18 months (range, 1 to 137+ months). Median survival time was 17 months (range, 0.5 to 138+ months) with a 3-year survival rate of 31%. Twenty-three patients (53%) relapsed between 1 and 58 months after entering remission with reinduction therapy resulting in 8 CRs (35%). Thirteen characteristics were examined for an effect on survival. The most striking finding was a significant association between elevated absolute granulocyte count and poor survival (P = .002). WBC count greater than 10,000/microL was also associated with shorter survival (P = .05). Patient age, albumin level, and platelet count showed trends for survival association. Although patients with AML and t(8;21) are regarded as a favorable group with respect to survival, we found a subset of patients who do very poorly. Intensive or more investigational approaches in first remission should be considered for these patients.
Indoor pollution and poor ventilation inside the houses synergize to cause airflow limitation in non smokers high altitude dwellers
Authors: Luca Pomidori, Manuela Bartesaghi, Buddha Basnyat, Rosa Maria Bruno, Enrico Duo, Giuseppe Miserocchi, Lorenza Pratali, Ramesh Sharma, Kamal Tapa, Annalisa Cogo
Journal: European Respiratory Journal (2012)

Indoor air pollution from biomass fuel smoke is linked to respiratory diseases. We performed spirometry in 3 villages of a nepalese valley where neither traffic nor industries are present, people use biomass fuels for heating and cooking, often without a chimney, and have a very low smoke habit (4%) so that only the effect of indoor pollution can be investigated. We meausered the ventilation inside the houses (Ventilation Index [VI]= window surface/kitchen cubic meters) and the environmental (not reported) and exhaled carbon monoxide as a surrogate marker of indoor pollution. A total of 304 subjects performed acceptable and reproducible spirometry. We calculated the % of subjects with non reversible bronchial obstruction (GOLD) and the % of subjects with FEF25-75   Exhaled CO and VI are negatively correlated (p 0.002). We conclude that subjects living in poorly ventilated houses and only exposed to indoor pollution have a high incidence of COPD and of abnormalities of FEF25-75 which could be interpreted as an early marker of bronchial obstruction (Pellegrino R et al, 2005).  *p   Funded by Ev-K2-CNR, Italy.
Tardive and Withdrawal Dyskinesia Associated with Haloperidol
Authors: GARY JACOBSON, ROSS J. BALDESSARINI, THEO MANSCHRECK
Journal: American Journal of Psychiatry (1974)

Four cases of dyskinesia attributable to treatment with 4-20 mg. of haloperidol daily for more than a year are reported. Two cases involved temporary oral-facial dyskinesias and the others a more persistent complex mixture of neurological features. The possibility that tardive dyskinesia may be associated with the butyrophenones in addition to other antipsychotic agents should be considered, the authors believe.
Examination of General and Tumor-Specific Cell-Mediated Immune Responses in Mice Bearing Progressively Growing Plasmacytomas 2
Authors: M. L. Padarathsingh, J. L. McCoy, J. H. Dean, D. D. Lewis, J. W. Northing, L. W. Law
Journal: JNCI Journal of the National Cancer Institute (1977)

General and tumor-specific cell-mediated immunity was investigated in BALB/c mice bearing progressively growing mineral oil-induced plasmacytoma ADJ-PCS, which was previously known to possess tumor-associated antigens (TAA). Lymphocyte blastogenesis (LB) assays demonstrated that the levels of blastogenesis to T- and B-cell mitogens in spleen cells of tumor-bearing mice were severely depressed in the early as well as the late stages of tumor growth. Total eradication of the palpable tumor after chemotherapy with aniline mustard resulted in recovery of the general T- and B-cell immunocompetence. Spleen cells from mice bearing medium-sized to large (15–30 mm in diameter) subcutaneous ADJ-PC5 tumors, shown to be generally depressed to mitogens by LB assays, nevertheless retained strong tumor-specific neutralizing immunity in Winn assays against ADJ-PC5 tumor cells. Specificity of the ADJ-PC5-directed immunity was confirmed by the failure of ADJ-PC5-immune spleen cells to neutralize a Moloney virus-induced leukemia (LSTRA) or a simian virus 40-induced fibrosarcoma (mKSA). Likewise, established specific immunity against TAA of mKSA was not interrupted by progressive growth of ADJ-PC5 tumors in mKSA-immune mice. Results suggested that specific cell-mediated immunity against TAA of ADJ-PC5 or another tumor (mKSA) was left intact in animals bearing progressively growing ADJ-PC5 tumors, even though their spleen cell populations (T and B) demonstrated severely depressed lymphoproliferative responses toT- and B-cell mitogens.
The predictive value of the COPD assessment test (CAT) for acute exacerbations in patients with chronic obstructive pulmonary disease (COPD)
Authors: Dimitar Sajkov, 黃明賢, Jian Kang, Ching-Hsiung Lin, Myung Jae Park, Namhee Kwon, Sang-Do Lee
Journal: European Respiratory Journal (2012)

Acute exacerbations significantly impair health-related quality of life (QoL) and productivity of patients with COPD. Predicting the probability of exacerbation may help in optimising COPD management. We evaluated whether the COPD Assessment Test (CAT™) could predict the risk of future exacerbations of COPD.  COPD patients with a history of exacerbation were recruited from 19 sites in four Asia Pacific countries. CAT score, Medical Research Council (MRC) dyspnea score, spirometry data, medical history, and exacerbation episodes were prospectively collected over six months.  In 495 evaluable patients with a mean age of 69.4±8.8 years, 68% had at least one exacerbation over the study period. The baseline CAT score categorised into four severity groups showed a strong predictive value for time to first exacerbation (Area under the curve [AUC]=0.83). Time to first exacerbation was shorter with worsening category of CAT score (p=0.001; mean 19.9, 15.8, 10.9 and 4.5 weeks for CAT scores categories of 0–9, 10–19, 20–29 and 30–40 respectively; adjusted hazard ratios of 1.0, 1.53, 2.08 and 3.41 respectively). CAT score category, however, had a modest predictive ability for at least one exacerbation (AUC=0.64). The risk of future exacerbations was higher with worsening category of CAT score (p=0.004; adjusted relative risks: 1.0, 1.26, 1.33 and 1.45 respectively). The uncategorised CAT scores, used as a continuous variable, found predictions of similar magnitude.  In outpatients with COPD, the baseline CAT score showed a strong predictive value for time to first exacerbation. It also provided modest prediction of exacerbations in the following six months.
Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial.
Authors: R L Burkes, R J Ginsberg, F A Shepherd, M E Blackstein, M E Goldberg, P F Waters, G A Patterson, T Todd, F G Pearson, J D Cooper
Journal: Journal of Clinical Oncology (1992)

PURPOSE The 5-year survival rates with surgical resection for preoperatively identified stage IIIA N2 non-small-cell lung cancer (NSCLC) are less than 10%. A pilot study of mitomycin, vindesine, and cisplatin (MVP) induction chemotherapy was undertaken in an attempt to improve the curative potential of surgery in this group of patients. PATIENTS AND METHODS Thirty-nine patients with mediastinoscopy stage IIIA N2 NSCLC received two cycles of MVP. Responding patients underwent thoracotomy for resection and two further courses of MVP. RESULTS The overall response rate was 64% (25 of 39) with three complete and 22 partial responses. Twenty-two patients were resected, which included a radical mediastinal node dissection. Eighteen resections were complete and four were incomplete. Pathologically, three patients (7.7%) had no tumor remaining. Toxicity included two postoperative deaths secondary to a bronchopleural (BP) fistula, mitomycin pulmonary toxicity in two patients, and septic deaths in four patients. Twenty-eight patients have died; 20 have recurrent or progressive disease. Eight of the 18 patients completely resected have recurred, with a median time to recurrence of 20.6 months. Sites of recurrence include two locoregional, five distant (two in brain), and one in both. Median survival of all 39 patients is 18.6 months, with a 3-year survival of 26%. The median survival for those patients completely resected was 29.7 months with a 3-year survival of 40%. CONCLUSIONS We conclude (1) that MVP is an effective but toxic chemotherapeutic regimen for limited NSCLC; (2) the median survival seems to be prolonged; and (3) the role of induction chemotherapy followed by surgery in stage IIIA N2 NSCLC requires a phase III randomized trial to compare it with other treatment modalities.
Everolimus Causing Severe Hypertriglyceridemia and Acute Pancreatitis
Authors: Somasundaram Subramaniam, Jason A. Zell, Pamela L. Kunz
Journal: Journal of the National Comprehensive Cancer Network (2013)

Everolimus is an mTOR inhibitor commonly used to treat metastatic pancreatic neuroendocrine tumors (pNETs) and renal cell carcinoma, and for posttransplant immunosuppression. This report presents a case of a 36-year-old man being treated with everolimus for a metastatic pNET who developed severe hypertriglyceridemia and acute pancreatitis. The incidence of hypertriglyceridemia reported in large prospective randomized trials is reviewed and the management of hypertriglyceridemic pancreatitis is discussed. Careful monitoring of triglyceride levels and dose adjustments of everolimus together with lipid-lowering therapy can allow patients to continue this medication. Because there are increasing indications for the use of everolimus, prescribing oncologists must be cognizant of the common and serious side effects.
Primary Care Provider-Delivered Smoking Cessation Interventions and Smoking Cessation Among Participants in the National Lung Screening Trial
Authors: Elyse R. Park, Ilana F. Gareen, Sandra Japuntich, Inga Lennes, Kelly Hyland, Sarah DeMello, JoRean D. Sicks, Nancy A. Rigotti
Journal: JAMA Internal Medicine (2015)

The National Lung Screening Trial (NLST) found a reduction in lung cancer mortality among participants screened with low-dose computed tomography vs chest radiography.In February 2015, Medicare announced its decision to cover annual lung screening for patients with a significant smoking history.These guidelines promote smoking cessation treatment as an adjunct to screening, but the frequency and effectiveness of clinician-delivered smoking cessation interventions delivered after lung screening are unknown.OBJECTIVE To determine the association between the reported clinician-delivered 5As (ask, advise, assess, assist [talk about quitting or recommend stop-smoking medications or recommend counseling], and arrange follow-up) after lung screening and smoking behavior changes. DESIGN, SETTING, AND PARTICIPANTSA matched case-control study (cases were quitters and controls were continued smokers) of 3336 NLST participants who were smokers at enrollment examined participants' rates and patterns of 5A delivery after a lung screen and reported smoking cessation behaviors. MAIN OUTCOMES AND MEASURESPrevalence of the clinician-delivered 5As and associated smoking cessation after lung screening.RESULTS Delivery of the 5As 1 year after screening were as follows: ask, 77.2%; advise, 75.6%; assess, 63.4%; assist, 56.4%; and arrange follow-up, 10.4%.Receipt of ask, advise, and assess was not significantly associated with quitting in multivariate models that adjusted for sociodemographic characteristics, medical history, screening results, nicotine dependence, and motivation to quit.Assist was associated with a 40% increase in the odds of quitting (odds ratio, 1.40; 95% CI, 1.21-1.63),and arrange was associated with a 46% increase in the odds of quitting (odds ratio, 1.46; 95% CI, 1.19-1.79). CONCLUSIONS AND RELEVANCEAssist and arrange follow-up delivered by primary care providers to smokers who were participating in the NLST were associated with increased quitting; less intensive interventions (ask, advise, and assess) were not.However, rates of assist and arrange follow-up were relatively low.Our findings confirm the need for and benefit of clinicians taking more active intervention steps in helping patients who undergo screening to quit smoking.
MCM2 Is an Independent Predictor of Survival in Patients With Non–Small-Cell Lung Cancer
Authors: Nithya Ramnath, Francisco J. Hernandez, Dong-Feng Tan, Joel A. Huberman, Nachimuthu Natarajan, Amy F. Beck, Andrew Hyland, Ivan T. Todorov, John S.J. Brooks, Gerold Bepler
Journal: Journal of Clinical Oncology (2001)

PURPOSE: Minichromosome maintenance protein 2 (MCM2) is a component of the prereplicative complex. It is essential for eukaryotic DNA replication and is only expressed in proliferating cells. The prognostic utility of MCM2 compared with Ki-67, another marker of proliferating cells, on survival of patients with non–small-cell lung cancer (NSCLC) was studied. PATIENTS AND METHODS: We examined the immunohistochemical expression of MCM2 and Ki-67 in primary pathologic tumor specimens from 221 NSCLC patients. For each marker, the fraction of tumor cells with positive staining was assessed as a percentage and categorized into four groups: 0% to 24%, 25% to 49%, 50% to 74%, and ≥ 75%. MCM2 and Ki-67 immunoreactivities were compared with each other, and associations with pathologic and clinical parameters predictive of survival were analyzed with the χ 2 test. Cox regression models were used to assess associations between MCM2 and Ki-67 and survival while controlling for confounders. RESULTS: Independent variables significantly associated with survival were tumor stage, performance status, and staining category. Patients with less than 25% MCM2 immunoreactivity had a longer median survival time than patients with ≥ 25% MCM2 immunoreactivity (46 v 31 months; P = .039) and a lower relative risk (RR) of death (RR, 0.55, 95% confidence interval, 0.34 to 0.88). There was no significant association between survival and Ki-67 expression. CONCLUSION: Immunostaining of tumor cells for MCM2 is an independent prognostic parameter of survival for patients with NSCLC. Interpretable results can be obtained on more than 96% of paraffin-embedded specimens, and approximately 35% will be in the favorable subgroup, with less than 25% positively stained tumor cells. Whether MCM2 is predictive of response to therapy needs to be studied.
Subcutaneous fat necrosis of the newborn
Authors: TAKUO TSUJI
Journal: British Journal of Dermatology (1976)

Specimens from two cases of subcutaneous fat necrosis of the newborn were studied by light and electron microscopy. Crystallization of the fat cell started with clearing of the central fat droplet, followed by the appearance of cylindrical crystals. The fat crystals were phagocytoscd by cytoplasmic projections of macrophages as well as by foreign body giant cells. Calcium deposits were demonstrated within the central fat droplet of the degenerated fat cell of Case 2.